The FDA has issued a warning regarding Abbott's FreeStyle Libre 3 glucose monitor sensors due to potential inaccuracies that could lead to serious health risks. This warning follows reports linking these devices to 736 serious injuries and seven fatalities. Despite these challenges, Abbott Laboratories maintains a robust financial profile and global market presence, characterized by strong profitability and efficient operations.

雅培

<p>美國食品藥品監督管理局（FDA）已對雅培的 FreeStyle Libre 3 血糖監測傳感器發出警告，原因是可能存在不準確性，這可能導致嚴重的健康風險。此警告是在報告將這些設備與 736 起嚴重傷害和七起死亡事件聯繫起來之後發佈的。儘管面臨這些挑戰，雅培仍保持強健的財務狀況和全球市場存在，表現出強大的盈利能力和高效的運營</p>

美國食品藥品監督管理局（FDA）對雅培（ABT）葡萄糖監測儀發出警告，此前有報告稱該設備與死亡事件有關